Navigation Links
Resverlogix Activates First Site for ASSURE 1 Clinical Trial
Date:2/25/2010

compared to placebo control. In half of the patients a change in atherosclerosis will be assessed, i.e. change in plaque volume and plaque composition. The primary objective of this study is to determine the 3 month effect of RVX-208 on change in the plasma levels of ApoA-l in patients with a recent ACS event who require coronary angiography versus placebo. The secondary objectives for this study include assessing the safety and tolerability of the drug through evaluation of adverse events as well as to evaluate the effect of RVX-208 on other lipid parameters.

"There are a number of people who are very pleased that we are able to announce the beginning of our IVUS study. Much planning has been undertaken with our international experts who reside on our IVUS Steering Committee and Clinical Advisory Committee. We are pleased to be able to bring RVX-208 to acute coronary syndrome patients, a group that presents with high cardiovascular risk," said Dr. Allan Gordon, Senior Vice President Clinical Development of Resverlogix Corp.

Resverlogix clinical program is expanding. In unrelated news Resverlogix is pleased to announce today the appointment of Ms. Tina Rarick to the position of Vice President Project Management & Business Operations. Tina recently joined Resverlogix after working for the past six years as a Global Project Manager for Roche Pharmaceuticals. Previous to this Tina was with several pharmaceutical firms including Schering-Plough and SUGEN/Pharmacia. Earlier in her career Ti
'/>"/>

SOURCE Resverlogix Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Resverlogix Completes Patient Recruitment for ASSERT Trial
2. Arthur J. Higgins, CEO of Bayer HealthCare, Appointed to Resverlogix Board of Directors
3. Resverlogix Presenting at Biotech Showcase
4. Resverlogix Commences Phase 2 Atherosclerosis Clinical Trial
5. Resverlogix Updates Shareholders on Accelerated Clinical Trial Plan
6. Resverlogix Appoints A. Brad Cann as Chief Financial Officer
7. Resverlogix RVX-208 Second Clinical Trial Demonstrates Success on Key Reverse Cholesterol Transport Markers
8. Resverlogix Phase 1b/2a Study Meets Primary Endpoint
9. Resverlogixs Success in Inflammation Program Results in 2 Patents Filed
10. Resverlogix Provides Quarterly Update
11. Resverlogix Board of Directors Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... 02, 2014 For the past ... under the auspices of the Armed Forces Institute ... of academic research organizations in the development of ... AFIRM is a multi-institutional, inter¬disciplinary network working to ... injuries suffered by US servicemen and women in ...
(Date:8/1/2014)... of topological electron flow in certain semiconductors. In ... of the material but not through the bulk. ... impurities in the material the electrons will continue to ... In the photonic equivalent, light flows not through and ... of an array of tiny glass loops fabricated on ...
(Date:8/1/2014)... Shreveport, LA (PRWEB) August 01, 2014 Chantel ... to conduct research for 10 40-hour weeks with Dr. Juan ... effects of diabetic retinopathy, a common diabetic eye disease caused ... , "What Chantel and Eli accomplished is quite remarkable,” ... was only a concept when they started, and together carried ...
(Date:8/1/2014)... Applied DNA Sciences, Inc. ... technology and product authentication solutions, will host a conference ... fiscal third quarter results. The Quarterly Report on Form ... end of the day on Monday August 11, 2014. ... a conference call beginning at 9:00 A.M. Eastern Daylight ...
Breaking Biology Technology:Wounded Warriors a Focus of the 12th New Jersey Symposium on Biomaterials Science 2On-chip topological light 2On-chip topological light 3Two Centenary College Students Tackle Diabetic Retinopathy Research 2Applied DNA Sciences to Host Conference Call Tuesday August 12, 2014 2Applied DNA Sciences to Host Conference Call Tuesday August 12, 2014 3
... 3 Metabolex, Inc., a,biopharmaceutical company focused ... medicines for the treatment of metabolic diseases,announced ... MBX-8025) have been,recognized in Windhover,s "Top 10 ... respective categories. MBX-2982, a potential,first-in-class treatment for ...
... Sunesis,Pharmaceuticals, Inc. (Nasdaq: SNSS ), a biopharmaceutical ... therapeutics for,the treatment of solid and hematologic cancers, today ... upcoming conferences:, Rodman & Renshaw 10th Annual Healthcare ... Wednesday, November 12, 2008, 2:00 p.m. EST, ...
... Catalyst,Pharmaceutical Partners, Inc. (Nasdaq: CPRX ) a ... prescription,drugs for the treatment of drug addiction and ... Chief Executive,Officer, will be presenting an overview of ... Global Investment Conference on Tuesday, November 11,2008 at ...
Cached Biology Technology:Two Metabolex Projects Recognized in Windhover's Top 10 Lists for Partnering Opportunities 2Two Metabolex Projects Recognized in Windhover's Top 10 Lists for Partnering Opportunities 3Sunesis to Present at Upcoming Conferences 2Catalyst Pharmaceutical Partners to Present at the Rodman & Renshaw 10th Annual Global Investment Conference 2
(Date:7/31/2014)... According to the U.S. Census Bureau, Latinos are the ... of the population. Approximately one-third of Latinos are ... obese compared to non-Hispanic Whites. , NYU College ... candidate, has sought to identify the factors that contribute ... qualitative studies that focused on food patterns in Latina ...
(Date:7/31/2014)... follow-up study (HPV-023; NCT00518336) shows the sustained ... papilloma virus (HPV) vaccine Cervarix. Women vaccinated ... for more than nine years, and vaccine ... This is the longest follow-up report for ... for the full paper. , ...
(Date:7/31/2014)... international team of scientists from Spain, France, and ... beetle that is the oldest definitive member of ... in amber. The discovery and description were made ... X-ray synchrotron imaging technique, which allows the detailed ... The new species is described in the journal ...
Breaking Biology News(10 mins):NYU research looks to combat US Latina immigrant obesity 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 3
... whole organism, as they may lead to life-threatening illnesses ... report how byproducts of respiration cause mispairing of subunits ... cells controls the form and function of every cell ... encoded in the linear sequence of the four subunits ...
... , NEW YORK, May 22, 2013. Plastic additives ... and just about everywhere: They turn up in ... tubing andaccording to the Centers for Disease Control ... as harmless, phthalates have come under increasing scrutiny. ...
... occur in the body, stem cells in the blood ... mature immune cells that can fight off illness. But ... potentially leading to the development of serious blood conditions ... by biologists at the California Institute of Technology (Caltech) ...
Cached Biology News:DNA damage: The dark side of respiration 2Study links chemicals widely found in plastics and processed food to elevated blood pressure in children and teens 2Keeping stem cells strong 2
... a score of movement counts, similar to an ... up to 6 subjects at once, in two ... Test a whole experimental group at once, and ... Upgradeable for a variety of other spatial ...
... OutputCumulates a score of movement counts, similar to ... track up to 6 subjects at once, in ... Can outpt a sync pulse to coordinate ... use animal location and timing information to control ...
... Place AvoidanceIncludes all features of Tracker, plus software ... user defined subsection of the arena, and trigger ... of instruments all built around a video camera, ... can track two fields at once and up ...
... for foraging behavior.The Spatial Behavior line is a ... camera, frame grabber, and feature extraction software and ... up to 6 moving animals. Software automatically ... allows video replay of all or machine-selected events. ...
Biology Products: